Risk assessment Webinars/Videos

  • Running time: 35 minutes, 49 seconds

     

    00.16 Lp(a) structure and metabolism

    01.51 Elevated Lp(a) prevalence and risk of cardiovascular diseases

    02.38 Factors influencing Lp(a) level

    03.35 Physiological functions of Lp(a)

    04.12 Atherogenicity of Lp(a)

    04.56 Clinical implication of Lp(a) elevation

    05.25 Genetic variants associated with increased Lp(a) concentrations

    05.44 Association between high Lp(a) level and risk of various cardiovascular diseases

    07.43 Clinical implication of Lp(a) elevation at low LDL-C

    08.47 Lp(a) categories increases absolute baseline risk of traditional risk factors

    09.40 Is reducing Lp(a) physiologically safe?

    10.34 Strategies to lower Lp(a) level

    11.57 Future directions in Lp(a) research

    12.37 Summary

    Video Library

    Lp(a):What is it and its role in atherosclerosis

    In this video, Prof. Lale Tokgozoglu of Hacettepe University, former president of the European Atherosclerosis Society, discusses the structure, function, and genetics of Lp(a) and highlights the clinical implications of elevated Lp(a) levels. Using evidence from contemporary clinical studies, Prof. Tokgozoglu shares insights into approaches for lowering Lp(a) levels. Finally, challenges in the comprehensive understanding of the physiological and clinical implications of Lp(a) are discussed. Learning outcome – High levels of lipoprotein(a) increase the chances of experiencing heart attack, stroke, and aortic stenosis.

    Prof. S. Lale Tokgözoğlu

    First published: March 11, 2024  

    View

  • Video Library

    Lipid measurements in the management of cardiovascular diseases

    In this video, Prof. Stephen Nicholls provides a comprehensive overview of our infographic on lipid measurements and their clinical implications, serving as a helpful resource for healthcare professionals involved in managing cardiovascular disease. Covering atherogenic dyslipidemia, lipid profile components, advanced tests, and genetic considerations, Prof. Nicholls emphasizes individualized approaches to interpreting lipid parameters based on patient demographics and risk levels. This aims to guide clinicians in optimizing lipid-lowering therapy for cardiovascular risk prevention.

    First published: March 6, 2024  

    View

  • Running time: 58 minutes, 46 seconds

     

    01.28 Concept of cumulated LDL exposure (mg-years)

    05.11 Re-defining secondary prevention

    08.04 Early secondary prevention

    11.27 Late secondary prevention (CHD)

    19.17 Late secondary prevention (PAD)

    20.15 Very late secondary prevention (ACS)

    23.18 Longer is better

    24.55 Earlier is better

    26.21 Younger is better

    28.39 Older Adults also deserve treatment

    41.12 Audience Q&A

    Video Library

    “Lower, Longer, Sooner, Earlier, and Younger”: Do we have enough evidence?

    Prof. Chiang discusses Atherosclerotic Cardiovascular Disease (ASCVD) in context of cumulated LDL exposure, and the different stages of secondary prevention and how starting to manage the disease at a younger age or earlier stage is beneficial. At 41:12 he answers audience questions.

    First published: October 25, 2023  

    View

  • Running time: 35 minutes, 49 seconds

     

    00.00 Patients and plaque

    03.30 Pictorial representation and
    primary prevention or adherence

    07.00 Calcium Scoring

    13.00 Other targets: Lp(a)

    21.00 Triglycerides

    28.00 Special: Latest data from ESC

    Video Library

    ASCVD Roundtable Part 2: Other targets and ESC 2023 Highlights

    In this second part of the Round Table conversation, the Editorial Panel discuss how showing patients’ images of their plaques help with adherence, discuss other targets such as Lp (a) and triglycerides and most importantly, discuss some of the latest data from the recently concluded ESC congress.

    Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt

    First published: September 1, 2023  

    View

  • Running time: 25 minutes, 25 seconds

     

    00.00 Introduction

    01.21 LDL target and guidelines

    07.55 Should we start combination
    therapy early?

    12.35 Side effects of combination
    therapy?

    16.40 Dosing in combination
    therapy – Inclisiran

    Video Library

    ASCVD Roundtable Part 1: Target guidelines, dosing, and compliance in lipid lowering therapies

    In recognition of the ASCVD & Lipidology Knowledge Hub 2 year anniversary, the esteemed faculty members for this educational resource site met to discuss the hot topics that have occurred over this time. Come and take a seat at this roundtable discussion with Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, and Prof. Deepak Bhatt as they discuss target guidelines, dosing, and compliance in lipid lowering therapies.

    Prof. Christopher P. Cannon, Prof. Chern-En Chiang, Prof. Stephen Nicholls, Prof. S. Lale Tokgözoğlu, Prof. Deepak Bhatt

    First published: August 1, 2023  

    View